FY2027 EPS Estimates for McKesson Decreased by Analyst

McKesson Co. (NYSE:MCK - Free Report) - Equities research analysts at Leerink Partnrs lowered their FY2027 EPS estimates for McKesson in a research note issued to investors on Wednesday, April 2nd. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings per share of $41.75 for the year, down from their previous forecast of $41.98. The consensus estimate for McKesson's current full-year earnings is $32.77 per share. Leerink Partnrs also issued estimates for McKesson's FY2027 earnings at $41.75 EPS.

Several other equities research analysts have also recently issued reports on MCK. Morgan Stanley increased their price target on McKesson from $642.00 to $745.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 2nd. Evercore ISI raised their price target on McKesson from $650.00 to $675.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Bank of America dropped their price target on McKesson from $680.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, January 6th. Wells Fargo & Company raised their target price on shares of McKesson from $641.00 to $691.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Finally, Mizuho upped their price target on shares of McKesson from $630.00 to $690.00 and gave the stock a "neutral" rating in a report on Thursday, April 3rd. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $661.00.

Remove Ads

McKesson Price Performance

McKesson stock traded down $9.09 during midday trading on Friday, hitting $652.88. The company's stock had a trading volume of 1,473,873 shares, compared to its average volume of 867,795. The company has a 50-day moving average price of $634.52 and a two-hundred day moving average price of $587.00. McKesson has a 1-year low of $464.42 and a 1-year high of $728.32. The company has a market cap of $81.82 billion, a price-to-earnings ratio of 29.89, a PEG ratio of 1.29 and a beta of 0.49.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing analysts' consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Monday, March 3rd were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Monday, March 3rd. This represents a $2.84 annualized dividend and a yield of 0.43%. McKesson's dividend payout ratio is presently 13.00%.

Insiders Place Their Bets

In other McKesson news, EVP Leann B. Smith sold 188 shares of the company's stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total value of $114,602.92. Following the sale, the executive vice president now owns 1,051 shares in the company, valued at approximately $640,679.09. The trade was a 15.17 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Brian S. Tyler sold 8,961 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $597.99, for a total value of $5,358,588.39. Following the transaction, the chief executive officer now owns 60,664 shares of the company's stock, valued at $36,276,465.36. This trade represents a 12.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,110 shares of company stock valued at $10,855,706 in the last ninety days. 0.11% of the stock is currently owned by insiders.

Institutional Trading of McKesson

Several institutional investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. boosted its stake in shares of McKesson by 8.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,847,385 shares of the company's stock valued at $1,622,754,000 after purchasing an additional 222,496 shares during the last quarter. Geode Capital Management LLC lifted its holdings in McKesson by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 2,663,303 shares of the company's stock valued at $1,513,195,000 after buying an additional 10,015 shares during the period. Franklin Resources Inc. boosted its position in McKesson by 4.6% during the fourth quarter. Franklin Resources Inc. now owns 2,620,948 shares of the company's stock valued at $1,493,704,000 after acquiring an additional 114,396 shares during the last quarter. GAMMA Investing LLC grew its holdings in McKesson by 75,632.7% during the 1st quarter. GAMMA Investing LLC now owns 2,393,152 shares of the company's stock worth $1,610,567,000 after acquiring an additional 2,389,992 shares during the period. Finally, Norges Bank bought a new position in shares of McKesson in the 4th quarter worth about $1,200,361,000. 85.07% of the stock is currently owned by institutional investors.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.